News

Ipsen is recruiting participants for a trial assessing the safety and efficacy of elafibranor in primary biliary cholangitis (PBC).

A recent study showed the PTPN2 gene may be associated with increased risk for primary biliary cholangitis (PBC).

According to interim phase 2 data, golexanolone has a favorable safety and tolerability profile in people with PBC.

A recent study shows prompt identification of extrahepatic conditions (EHCs) is of key importance for the precise, timely diagnosis of PBC.

Ascletis has decided not to pursue additional clinical trials on the farnesoid X receptor (FXR) agonist ASC42 for the treatment of PBC.

A study found that cholestatic pruritus is under-documented in patient medical records, compared to patient-reported responses.

The European Medicines Agency has accepted for review the Marketing Authorization Application (MAA) for seladelpar in PBC.

The FDA has accepted the supplemental New Drug Application for Intercept’s Ocaliva for the treatment of PBC.

The drug elafibranor appears to be effective and safe for the treatment of primary biliary cholangitis (PBC) in a phase 3 trial.

Using a two-sample Mendelian randomization (MR) analysis, researchers found a genetic association between PBC and CTDs.